Antiviral drugs under development in the SCORE consortium update 2022:
- The antiviral drug 13b-K, a viral inhibitor of SARS-CoV-2 Mpro
- The drug line series 06, an antiviral specific for SARS-CoV-2 (see SCORE newsletters)
- The drug line series 08, a broad spectrum coronavirus antiviral which is further developed within the CARE consortium (see SCORE newsletters)
- HR2 entry inhibitors for SARS-CoV-2
- SAR405, an inhibitor of the host VPS34 (class III PI3K).
- Suramin, a broad spectrum antiviral, is applied to SARS-CoV-2 with a new application method